Hermetica Superfood Encyclopedia
Legacy index-continuity record: the score and narrative are provisional and must not be represented as validated or human-approved.
Review flags: AWAITING_SEMANTIC_VALIDATION
Glycitein is an isoflavone phytoestrogen found in soybeans that functions as a selective estrogen receptor modulator with anti-cancer properties. It works primarily through estrogen receptor binding and inhibition of protein kinases involved in cell proliferation pathways.
Origin & History
Glycitein is an O-methylated soy isoflavone (6-methoxy substitution) that accounts for 5-10% of total isoflavones found in soybeans and soy products. It originates from soy germ (Glycine max) and is typically extracted through advanced purification techniques or obtained during soy food processing.
Research Narrative (Provisional)
Clinical evidence for glycitein alone is extremely limited. The only human trial identified was a phase I study (n=20 men with prostate cancer, n=6 controls) testing a soy isoflavone mixture containing glycitein at 300-600 mg genistein equivalents/day for 84 days, which showed no genotoxicity. Most evidence comes from preclinical cell culture and computational modeling studies.
Preparation & Dosage
Dosage guidance is withheld because the publication gate has not recorded adequate support for this profile.
Nutritional Profile
Glycitein is a minor soy isoflavone (phytoestrogen) belonging to the flavonoid subclass, constituting approximately 5-10% of total soy isoflavone content compared to genistein and daidzein which dominate. It is not a macronutrient or micronutrient itself but a bioactive polyphenolic compound. Molecular weight: 284.26 g/mol. Chemical structure: 7-hydroxy-6-methoxy-3-(4-hydroxyphenyl)-4H-chromen-4-one, distinguished from other soy isoflavones by a methoxy group at the C-6 position. Found in soy-based foods at concentrations of approximately 0.5-1.5 mg per 100g in whole soybeans, and up to 2-4 mg per 100g in some soy protein isolates. Present in three forms: aglycone (glycitein), glucoside conjugate (glycitin), and malonyl glucoside (6''-O-malonylglycitin). Bioavailability is moderate; intestinal microbiota hydrolyze glucoside forms to the active aglycone prior to absorption. Peak plasma concentrations typically reached within 4-8 hours post-ingestion. Demonstrates weak estrogenic activity (estimated 0.281% relative binding affinity compared to estradiol at ERα). No meaningful macro-, vitamin, mineral, or fiber content as it is a pure isolated phytochemical compound when studied.
Reported Mechanism (Provisional)
Glycitein acts as a selective estrogen receptor modulator (SERM), binding to both ERα and ERβ receptors with varying affinities. It inhibits protein kinase C and tyrosine kinases involved in cell signaling cascades. The compound also modulates NF-κB pathways and induces apoptosis through caspase activation in cancer cells.
Clinical Narrative (Provisional)
Preclinical studies demonstrate glycitein's cytotoxic effects on breast carcinoma cells at 100 μg/mL concentrations. In vitro research shows anti-proliferative activity against colon cancer cells through multiple molecular pathways. Animal studies suggest cardiovascular protective effects through lipid metabolism modulation. However, human clinical trials are limited, and most evidence remains at the laboratory stage with unclear therapeutic dosing.
Also Known As
Research updates — and 25% off your first order
Join our list for source-aware wellness education, review-state updates, and product news — and unlock 25% off your first Hermetica order. Educational content is not medical advice. No spam, unsubscribe anytime.